A Sussex-wide Immunotherapy Toxicity Service to Optimise Patient Care and Redistribute Workload from Tumour-specific Oncologists
2022; Elsevier BV; Volume: 34; Linguagem: Inglês
10.1016/j.clon.2022.01.035
ISSN1433-2981
AutoresL. Cheung, K. Mackay, E. Petrovics, Sharon A. Appleyard, Ali Hodge, C. Marrazes, S. Westwell,
Tópico(s)Immunotherapy and Immune Responses
ResumoBackground: Immunotherapy (IO) is in widespread use in a growing number of cancers. The toxicity profiles differ from traditional chemotherapies and present as autoimmune diseases which can be less familiar to oncology staff and other healthcare professionals. Prompt recognition, investigation and management of toxicities are important as some toxicities progress rapidly and without appropriate treatment may be fatal. There is no National Institute for Health and Care Excellence (NICE) guidance on IO toxicity management and guidance from international, UK and local bodies are heterogenous.
Referência(s)